drugset / Trial / NCT06327256

A Study in Healthy People to Test How Well Different Doses of BI 3000202 Are Tolerated and How They Affect the Way the Body Handles Midazolam

NCT06327256

Phase 1 Completed 40 enrolled Boehringer Ingelheim
RandomizedSequentialTriple-blindTreatment

Summary

The aim of this trial is to investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) following multiple rising doses of BI 3000202 and to investigate the effect of BI 3000202 on the metabolism of midazolam.

Timeline

Start
2024-04-09
Primary completion
2024-09-27
Completion
2024-09-27

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 3000202 Unknown
Subject Midazolam Small molecule

Indications

No indication recorded.